rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KYTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Kyverna completes BLA submission for autoimmune CAR-T therapy
      Nov 12Investing.comKYTX
      Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
      Nov 9Yahoo FinanceKYTX
      Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

      EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Thursday, November 19, 2026, at 10:00 am GMT. A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at i

      Nov 5Yahoo FinanceKYTXJEF
      Kyverna Therapeutics: Fascinating CAR-T Science, Tricky Commercial Outlook (NASDAQ:KYTX)

      Kyverna Therapeutics advances Miv-cel for autoimmune diseases, but valuation, launch, and funding risks remain. Click here to read this analysis on KYTX.

      Oct 28Seeking AlphaKYTX
      Kyverna reports phase 1 data for MS therapy miv-cel
      Oct 23Investing.comKYTX
      Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
      Oct 23Yahoo FinanceKYTX
      H.C. Wainwright reiterates Kyverna stock rating on full-year data
      Oct 22Investing.comKYTX
      Kyverna reports one-year data for SPS therapy miv-cel
      Oct 21Investing.comKYTX
      Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
      Oct 21Yahoo FinanceKYTX
      Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
      Oct 7Yahoo FinanceKYTX
      Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)

      Detailed price information for Kyverna Therapeutics Inc (KYTX-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailACADKYTX
      H.C. Wainwright reiterates Kyverna stock rating on durability data
      Sep 25Investing.comKYTX
      Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - Slideshow (NASDAQ:KYTX) 2026-09-24
      Sep 24Seeking AlphaKYTX
      Kyverna Delivers Relief in Rare Neurological Conditions - Kyverna Therapeutics (NASDAQ:KYTX)

      Kyverna Therapeutics reports positive one-year clinical trial data for miv-cel in stiff person syndrome and myasthenia gravis.

      Sep 24BenzingaKYTX
      Kyverna stock jumps on positive one-year therapy data
      Sep 24Investing.comKYTX
      Why is Kyverna Therapeutics stock surging today?
      Sep 24Investing.comKYTX
      Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials

      Kyverna Therapeutics (NASDAQ:KYTX) reported one-year topline data from its KYSA-8 registrational trial of miv-cel, or mivocabtagene autoleucel, in stiff person syndrome (SPS), alongside longer-term follow-up results from the Phase 2 portion of its KYSA-6 trial in generalized myasthenia gravis (gMG). The company said the latest results provide follow-up on clinical outcomes and safety measures after patients received a single dose of the investigational cell therapy.

      Sep 24Yahoo FinanceKYTX
      Kyverna reports one-year data for autoimmune CAR T therapy
      Sep 24Investing.comKYTX
      Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
      Sep 24Yahoo FinanceKYTX
      Kyverna at Morgan Stanley healthcare conference: first autoimmune CAR T launch
      Sep 14Investing.comKYTXMS
      Kyverna at wells fargo healthcare conference: autoimmune car t push advances
      Sep 9Investing.comKYTXWFC
      Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX)

      Detailed price information for Kyverna Therapeutics Inc (KYTX-Q) from The Globe and Mail including charting and trades.

      Sep 2The Globe and MailKYTX
      Kyverna Therapeutics to Present at Upcoming Investor Conferences

      EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences: 2026 Wells Fargo Healthcare ConferenceFormat: Fireside chat and investor meetingsDate: Wednesday, September 9th, 2026Time: 4:30 p.m. ET Morgan Stanley 24th Annual Global Healthcare Conf

      Sep 2Yahoo FinanceKYTX

      This is the newest page. Registered accounts read further back.